Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Antibiotic Drought Of 2008: Plenty Of Action But No NME Approvals

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The atypically small number of new molecular entity approvals from FDA's Office of Antimicrobial Products in 2008 belies the reviewers' full slate of NDAs, particularly of novel antibiotics

You may also be interested in...



UK Antibiotics Play Novacta Wins £13.1 million, mostly from Celtic Pharma

Funds should allow Novacta Biosystems to take three peptide-based ‘lantibiotics' programs through to proof-of-efficacy and secure a licensing deal

CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class

FDA’s second-half surge in approvals made 2008 the agency’s best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation.

CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class

FDA’s second-half surge in approvals made 2008 the agency’s best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel